SMT201600468T1 - Anticorpo che riconosce il fattore inibitorio della leucemia umano (lif) e uso di anticorpi diretti contro lif nel trattamento di patologie associate alla proliferazione cellulare indesiderata - Google Patents

Anticorpo che riconosce il fattore inibitorio della leucemia umano (lif) e uso di anticorpi diretti contro lif nel trattamento di patologie associate alla proliferazione cellulare indesiderata

Info

Publication number
SMT201600468T1
SMT201600468T1 SM201600468T SM201600468T SMT201600468T1 SM T201600468 T1 SMT201600468 T1 SM T201600468T1 SM 201600468 T SM201600468 T SM 201600468T SM 201600468 T SM201600468 T SM 201600468T SM T201600468 T1 SMT201600468 T1 SM T201600468T1
Authority
SM
San Marino
Prior art keywords
lif
recognizes
antibody
treatment
cell proliferation
Prior art date
Application number
SM201600468T
Other languages
English (en)
Inventor
Suarez Joan Seoane
Folgueira Judit Anido
Borderias Andrea Saez
Original Assignee
Fundacio Privada Institucio Catalana De Recerca I Estudis Avancants
Fundacio Privada Inst D Investigacio Oncologica Devall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Institucio Catalana De Recerca I Estudis Avancants, Fundacio Privada Inst D Investigacio Oncologica Devall Hebron filed Critical Fundacio Privada Institucio Catalana De Recerca I Estudis Avancants
Publication of SMT201600468T1 publication Critical patent/SMT201600468T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5415—Leukaemia inhibitory factor [LIF]
SM201600468T 2010-04-05 2016-12-22 Anticorpo che riconosce il fattore inibitorio della leucemia umano (lif) e uso di anticorpi diretti contro lif nel trattamento di patologie associate alla proliferazione cellulare indesiderata SMT201600468T1 (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10380049A EP2371860A1 (en) 2010-04-05 2010-04-05 Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation

Publications (1)

Publication Number Publication Date
SMT201600468T1 true SMT201600468T1 (it) 2017-03-08

Family

ID=42338260

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600468T SMT201600468T1 (it) 2010-04-05 2016-12-22 Anticorpo che riconosce il fattore inibitorio della leucemia umano (lif) e uso di anticorpi diretti contro lif nel trattamento di patologie associate alla proliferazione cellulare indesiderata

Country Status (25)

Country Link
US (3) US8926956B2 (it)
EP (3) EP2371860A1 (it)
JP (2) JP6289906B2 (it)
KR (5) KR102294207B1 (it)
CN (2) CN103797031A (it)
AU (1) AU2011237922B2 (it)
BR (1) BR112012025517B1 (it)
CA (1) CA2797257A1 (it)
CY (1) CY1119451T1 (it)
DK (1) DK2556091T3 (it)
EA (2) EA036698B9 (it)
ES (1) ES2608699T3 (it)
HK (3) HK1223384A1 (it)
HR (1) HRP20161736T1 (it)
HU (1) HUE030578T2 (it)
IL (3) IL222270A (it)
LT (1) LT2556091T (it)
MX (2) MX365054B (it)
PL (1) PL2556091T3 (it)
PT (1) PT2556091T (it)
RS (1) RS55539B1 (it)
SG (1) SG184429A1 (it)
SI (1) SI2556091T1 (it)
SM (1) SMT201600468T1 (it)
WO (1) WO2011124566A1 (it)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE040063T2 (hu) * 2005-07-19 2019-02-28 Stemgen S P A Tumor õssejtek tumorképzõ potenciáljának gátlása BMP-4 segítségével
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
WO2015040243A2 (en) * 2013-09-23 2015-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
TWI486172B (zh) * 2013-11-08 2015-06-01 Univ Chang Gung 鼻咽癌治療的醫藥
AU2015314980A1 (en) * 2014-09-10 2017-03-02 The Regents Of The University Of California Targeting K-Ras-mediated signaling pathways and malignancy by anti-hLIF antibodies
CA2981173C (en) 2015-03-23 2024-01-02 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
CN111868086A (zh) * 2016-12-19 2020-10-30 马赛克生物医学一人有限责任公司 抗lif抗体及其用途
WO2018115960A1 (en) 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3774895A1 (en) 2018-04-12 2021-02-17 MedImmune Limited Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
KR20210008514A (ko) * 2018-05-14 2021-01-22 메디뮨 리미티드 Lif에 대한 항체 및 이의 투여 형태
KR20210022065A (ko) * 2018-06-18 2021-03-02 메디뮨 리미티드 암을 치료하는 데 사용하기 위한 lif 억제제와 백금-기반 항신생물제의 조합
KR20220087457A (ko) * 2019-09-29 2022-06-24 자코바이오 파마슈티칼스 컴퍼니 리미티드 Lif에 특이적인 결합 분자 및 이의 용도
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
CN111378036B (zh) * 2020-01-09 2021-08-10 北京浩古元方生物医药科技有限公司 一种抗人白血病抑制因子单克隆抗体的制备方法及其应用
CN112294812B (zh) * 2020-11-18 2022-08-16 新乡医学院 一种小分子抑制剂在制备抗肿瘤药物方面的应用
CN114672460B (zh) * 2021-12-21 2023-06-23 中国人民解放军军事科学院军事医学研究院 一种靶向cd44的异质型cic细胞模型的制备方法及应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB9004890D0 (en) 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
JPH05304986A (ja) 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
AU4231393A (en) 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
WO1993023665A1 (en) 1992-05-15 1993-11-25 Re/Map Incorporated Electromagnetic shielding for a liquid conditioning device
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
CA2214636C (en) * 1995-04-24 2009-12-22 Genentech, Inc. Use of leukemia inhibitory factor and endothelin antagonists
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2003218456A1 (en) 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
AU2003262717A1 (en) * 2002-08-15 2004-03-03 Genzyme Corporation Brain endothelial cell expression patterns
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005030803A1 (en) 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
EP1752536A4 (en) 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
EP1612558A1 (en) 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CA2665447A1 (en) 2006-10-04 2008-04-10 The Scripps Research Institute Human antibodies neutralizing human metapneumovirus
CN101440128A (zh) * 2007-11-21 2009-05-27 中国人民解放军第二军医大学 人脑胶质瘤中差异表达的蛋白及其用途
WO2010054499A1 (en) * 2008-11-11 2010-05-20 Telefonaktiebolaget L M Ericsson (Publ) A dpd system with multiple transmitter paths
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
WO2011057144A2 (en) 2009-11-06 2011-05-12 La Jolla Institute For Allergy And Immunology Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
TWI486172B (zh) 2013-11-08 2015-06-01 Univ Chang Gung 鼻咽癌治療的醫藥

Also Published As

Publication number Publication date
EP2371860A1 (en) 2011-10-05
US20190119373A1 (en) 2019-04-25
EA201201373A1 (ru) 2013-04-30
JP2013523796A (ja) 2013-06-17
EP2556091A1 (en) 2013-02-13
EA036698B9 (ru) 2021-02-25
IL241952A (en) 2017-10-31
IL254664A0 (en) 2017-11-30
KR20170125137A (ko) 2017-11-13
KR20190061098A (ko) 2019-06-04
HK1223384A1 (zh) 2017-07-28
US10968273B2 (en) 2021-04-06
US20130142808A1 (en) 2013-06-06
JP2017019775A (ja) 2017-01-26
CN103797031A (zh) 2014-05-14
KR102294207B1 (ko) 2021-08-26
MX365054B (es) 2019-05-21
HK1208469A1 (en) 2016-03-04
SI2556091T1 (sl) 2017-02-28
EP3045473A1 (en) 2016-07-20
LT2556091T (lt) 2016-12-27
EA036698B1 (ru) 2020-12-09
HUE030578T2 (en) 2017-06-28
US20150139989A1 (en) 2015-05-21
KR20180078352A (ko) 2018-07-09
RS55539B1 (sr) 2017-05-31
CY1119451T1 (el) 2018-03-07
PL2556091T3 (pl) 2017-04-28
CA2797257A1 (en) 2011-10-13
IL254664B (en) 2022-03-01
HRP20161736T1 (hr) 2017-02-10
BR112012025517A2 (pt) 2017-11-28
SG184429A1 (en) 2012-11-29
WO2011124566A1 (en) 2011-10-13
IL222270A (en) 2016-06-30
JP6483059B2 (ja) 2019-03-13
CN109320609A (zh) 2019-02-12
AU2011237922B2 (en) 2014-07-10
EA202092276A3 (ru) 2021-04-30
IL222270A0 (en) 2012-12-31
ES2608699T3 (es) 2017-04-12
MX2012011636A (es) 2013-04-03
KR20130121679A (ko) 2013-11-06
DK2556091T3 (en) 2017-01-16
BR112012025517B1 (pt) 2021-08-31
KR20200119344A (ko) 2020-10-19
AU2011237922A1 (en) 2012-11-01
US8926956B2 (en) 2015-01-06
EA202092276A2 (ru) 2021-01-29
EP2556091B1 (en) 2016-09-28
HK1180702A1 (zh) 2013-10-25
JP6289906B2 (ja) 2018-03-07
PT2556091T (pt) 2017-01-03

Similar Documents

Publication Publication Date Title
SMT201600468T1 (it) Anticorpo che riconosce il fattore inibitorio della leucemia umano (lif) e uso di anticorpi diretti contro lif nel trattamento di patologie associate alla proliferazione cellulare indesiderata
SMT201600430B (it) Inibitori di chinasi e loro uso nel trattamento del cancro
IN2015DN01404A (it)
TWD169700S (zh) 針盤
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
CA141065S (en) Dual c clip
SMT201400008B (it) Uso di betanecolo per il trattamento di xerostomia
EP2566890A4 (en) ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
DK2342233T3 (da) Anti-CXCR4-antistoffer og anvendelse deraf i behandling af cancer
AU334234S (en) Clamp for fence panels
BRPI0914929A2 (pt) preparações cosméticas com prata passivada
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
TR201903840T4 (tr) İnsan tamamlayıcı C5'e bağlanan polipeptitler.
CO6790239A1 (es) Vidrios blindados curvos con vidrios, vitro- cerámicos o cerámicos curvados mecánicamente en la capa externa
UY34167A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
SG11202107274VA (en) Prostate neoantigens and their uses
SMAP201000048A (it) Uso di streptococcus salivarius nel trattamento delle infezioni croniche delle vie respiratorie
IT1397996B1 (it) Endoreattore e metodo di controllo della combustione nell'endoreattore stesso.
DK3052109T3 (da) Terapi med celler fra human placenta og hematopoietiske celler
IT1392140B1 (it) Reggipensile con mezzi perfezionati di fissaggio alla spalla del mobile pensile
ES1073064Y (es) Cajon flamenco con elementos de regulacion y mejora de sonido.
ES1074607Y (es) Mamparas de ducha y bano con puertas correderas guiadas mediante su apoyo en dos puntos diagonalmente opuestos
GB201703093D0 (en) Handbag with an installed built in portable bank
TH1001001802B (th) โพลีเปปไทด์ปรับภูมิคุ้มกันที่ได้มาจาก il-2 และประโยชน์ของพวกมันในการรักษาโรคมะเร็ง และการติดเชื้อแบบเรื้อรัง
FIU20090029U0 (fi) Luodin ja/tai puukon iskun kestävä reppu